Active ingredientZafirlukastCat. No. P-Z001-001CAS 107753-78-6Family · Pharmaceutical analytical standards
Zafirlukast
A CysLT1 leukotriene receptor antagonist, approved in the United States in 1996 for the prevention and long-term treatment of asthma in adults and children over five. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It was the first cysteinyl leukotriene receptor antagonist approved in the United States: it blocks the messengers released by eosinophils, basophils and lung macrophages that make the airways narrow.
Go to the active ingredient →Active ingredientZafirlukastCat. No. P-Z001-001CAS 107753-78-6
Isotopically labelledZafirlukast-d7Cat. No. P-Z001-004CAS 1217174-18-9
ImpurityHydroxy ZafirlukastCat. No. P-Z001-005
ImpurityN-Desmethyl N-Hydroxymethyl ZafirlukastCat. No. P-Z001-006
ImpurityZafirlukast Impurity 1Cat. No. P-Z001-007
ImpurityZafirlukast Impurity 2Cat. No. P-Z001-008
ImpurityZafirlukast Impurity 3Cat. No. P-Z001-009
ImpurityZafirlukast Impurity 4Cat. No. P-Z001-010CAS 107754-20-1
ImpurityZafirlukast Impurity 5Cat. No. P-Z001-011
ImpurityZafirlukast Impurity 6Cat. No. P-Z001-012CAS 1160235-26-6
ImpurityZafirlukast Impurity 7Cat. No. P-Z001-013
ImpurityZafirlukast Related Compound CCat. No. P-Z001-014CAS 1159195-67-1
ImpurityZafirlukast Related Compound DCat. No. P-Z001-015CAS 1159195-69-3
ImpurityZafirlukast Related Compound ECat. No. P-Z001-016CAS 1159195-70-6No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.